Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexFemale
Age18+
SponsorStony Brook University

About this trial

To determine the effectiveness of using two medications simultaneously versus one medication, as is standard of care, in preventing early postpartum hemorrhage.

There have been studies that looked at giving two medications and that there were reduced odds of postpartum hemorrhage.

Specific Aim 1: Determine if double simultaneous uterotonic agent regimen (misoprostol and oxytocin) is superior to single agent (oxytocin only) in reducing postpartum hemorrhage.

Specific Aim 2: Determine any potential side effects of a double simultaneous uterotonic agentregimen (misoprostol and oxytocin) versus a single agent (oxytocin only).

Eligibility criteria

Qualifiers

None

Disqualifiers

Women under 18 years old

Women with known coagulation disorders

Women with planned cesarean hysterectomy

Women with known placental accreta spectrum disorders

Trial design

Treatments tested in this trial

  • Sublingual Misoprostol
  • IV Oxytocin

Treatment groups

1,358 Participants
are divided into 2 treatment groups

Sponsors and collaborators